Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quick Listen: Scrip’s Five Must-Know Things

Progress, Setbacks And Coronavirus Vaccines

Executive Summary

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.

Take a brief audio tour around Scrip’s Five Must-Know Things, in this episode covering major developments in the business week ended 14 August 2020.

Making headlines this time are setbacks and progress for Roche, Bayer's external growth strategy, a controversial coronavirus vaccine approval and an infographic rundown of the world's top-selling drugs.

Stories mentioned in this episode:

(Also see "Roche’s Etrolizumab Failure ‘Removes Big Pipeline Opportunity’" - Scrip, 10 Aug, 2020.)

(Also see "Bayer Back In M&A Mode To Boost Pipeline" - Scrip, 12 Aug, 2020.)

(Also see "Russia Approves First COVID-19 Vaccine" - Scrip, 11 Aug, 2020.)

(Also see "Roche’s Evrysdi Approved For SMA, Priced Below Competitors" - Scrip, 7 Aug, 2020.)

(Also see "The Top 10 Best-Selling Drugs of 2019" - Scrip, 12 Aug, 2020.)

 

Related Content

Topics

UsernamePublicRestriction

Register

LL1133145

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel